BIOLINERX     Print Page  Close Window

2016 Press releases
E-mail Alerts Receive e-mail alerts | RSS Rss feeds
Keyword search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
12/05/16BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016Printer Friendly Version
11/22/16BioLineRx Reports Third Quarter 2016 Financial ResultsPrinter Friendly Version
11/21/16BioLineRx In-licenses Novel Anti-Inflammatory Treatment for Dry Eye Syndrome Under Strategic Collaboration with Major Global Pharmaceutical CompanyPrinter Friendly Version
11/15/16BioLineRx to Report Third Quarter Results on November 22, 2016Printer Friendly Version
11/03/16BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016Printer Friendly Version
10/05/16BioLineRx Announces Acceptance of BL-8040 Abstracts for Oral and Poster Presentations at 58th American Society of Hematology (ASH) Annual MeetingPrinter Friendly Version
09/23/16BioLineRx Announces In-licensing of Novel Treatment for Liver Failure Conditions Under Strategic CollaborationPrinter Friendly Version
09/22/16BioLineRx Ltd. Presents Corporate Objectives at Investor Breakfast Meeting in NYPrinter Friendly Version
09/20/16BioLineRx Announces Initiation of Phase 2a Trial of BL-8040 in Combination With KEYTRUDA® (pembrolizumab) for Treatment of Pancreatic CancerPrinter Friendly Version
09/09/16BioLineRx Ltd. to Host Investor Breakfast Meeting September 22, 2016 in New YorkPrinter Friendly Version
09/08/16BioLineRx Presents Final Results from Phase 2a Trial for Relapsed/Refractory AML at SOHO ConferencePrinter Friendly Version
09/07/16BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology IndicationsPrinter Friendly Version
08/29/16BioLineRx to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New YorkPrinter Friendly Version
08/25/16BioLineRx and I-Bridge Capital Establish a New Drug Development Joint Venture in ChinaPrinter Friendly Version
08/11/16BioLineRx Reports Second Quarter 2016 Financial ResultsPrinter Friendly Version
08/11/16BioLineRx Names Philip A. Serlin as Chief Executive OfficerPrinter Friendly Version
08/08/16BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic CancerPrinter Friendly Version
08/04/16BioLineRx to Report Second Quarter Results on August 11, 2016Printer Friendly Version
08/01/16BioLineRx Announces In-licensing of Liver Fibrosis Project Under Strategic CollaborationPrinter Friendly Version
06/28/16BioLineRx Announces Regulatory Submissions for Phase 2a Trial of BL-8040 in Combination with KEYTRUDA® (pembrolizumab) for Treatment of Pancreatic CancerPrinter Friendly Version
06/15/16BioLineRx to Present at the JMP Securities Life Sciences Conference in New YorkPrinter Friendly Version
05/19/16BioLineRx's BL-8040 to be Presented at Upcoming Scientific ConferencesPrinter Friendly Version
05/17/16BioLineRx Reports First Quarter 2016 Financial ResultsPrinter Friendly Version
05/16/16BioLineRx and MaRS Innovation Sign Framework Collaboration AgreementPrinter Friendly Version
05/10/16BioLineRx to Report First Quarter 2016 Results on May 17, 2016Printer Friendly Version
04/19/16BioLineRx Announces Presentation of Detailed Mechanism of Action Data for Lead Oncology Platform at AACR 2016Printer Friendly Version
04/04/16BioLineRx's Novel Treatment for Non-Surgical Removal of Skin Lesions Receives CE Mark ApprovalPrinter Friendly Version
03/29/16BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AMLPrinter Friendly Version
03/23/16BioLineRx Announces Initiation of Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization TreatmentPrinter Friendly Version
03/10/16BioLineRx Reports Year End 2015 Financial ResultsPrinter Friendly Version
03/10/16BioLineRx to Present at 2016 Annual Roth Conference in Southern California on March 14Printer Friendly Version
03/03/16BioLineRx to Report Annual 2015 Results on March 10, 2016Printer Friendly Version
02/01/16BioLineRx to Present at 2016 BIO CEO & Investor Conference in New York on February 8Printer Friendly Version
01/25/16BioLineRx Receives Confirmation of Medical Device Classification in Europe for Celiac TreatmentPrinter Friendly Version
01/12/16BioLineRx Announces Collaboration with MSD to Investigate the Combination of KEYTRUDA (pembrolizumab) and BL-8040 in Pancreatic CancerPrinter Friendly Version
01/04/16BioLineRx to Present at Biotech Showcase 2016 Conference in San FranciscoPrinter Friendly Version